BR0316882A - Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas - Google Patents

Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas

Info

Publication number
BR0316882A
BR0316882A BR0316882-4A BR0316882A BR0316882A BR 0316882 A BR0316882 A BR 0316882A BR 0316882 A BR0316882 A BR 0316882A BR 0316882 A BR0316882 A BR 0316882A
Authority
BR
Brazil
Prior art keywords
galactose
culture
sialylation
cell culture
methods
Prior art date
Application number
BR0316882-4A
Other languages
English (en)
Inventor
Bernhard M Schilling
Scott Gangloff
Dharti Kothari
Kirk Leister
Linda Matlock
Stephen G Zegarelli
Christoph E Joosten
Jonathan O Basch
Sivakesava Sakhamuri
Steven S Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0316882(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0316882A publication Critical patent/BR0316882A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MELHORA NA QUALIDADE DE PRODUTOS EM PROCESSOS DE CULTURA DE CéLULAS DE MAMìFEROS PARA A PRODUçãO DE PROTEìNAS". A presente invenção refere-se a métodos e processos para a produção de proteínas, particularmente glicoproteínas, por cultura de células animais ou de mamíferos, de forma ilustrativa, mas não limitada às culturas de células em batelada alimentada. Os processos compreendem a alimentação das células com a D-galactose, preferencialmente com meio de alimentação contendo a D-galactose, preferencialmente diariamente, para sustentar um nível eficiente de sialilação da D-galactose na cultura ao longo de sua duração, aumentando assim a sialilação das proteínas produzidas. Os processos podem ainda compreender pelo menos duas alterações na temperatura realizadas durante o período de cultivo, em que a temperatura é menor no final do período de cultivo do que no momento da cultura de células inicial. Os processos de cultura de células da invenção que envolvem duas ou mais alterações na temperatura sustentam uma alta viabilidade celular e podem permitir uma fase de produção de proteínas estendida. Os processos também podem compreender a adição retardada do composto polianiónico em um momento após a inoculação. A suplementação das culturas com a D-galactose, preferencialmente em um meio de alimentação, para sustentar a galactose em níveis eficientes de sialilação nas culturas até o final de uma rodada de cultura reverte um declínio na sialilação que acompanha o aumento de escala da cultura e é vantajosa para os processos de cultura em grande escala.
BR0316882-4A 2002-12-23 2003-12-18 Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas BR0316882A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43605002P 2002-12-23 2002-12-23
PCT/US2003/040939 WO2004058944A2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production

Publications (1)

Publication Number Publication Date
BR0316882A true BR0316882A (pt) 2005-10-25

Family

ID=32682324

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316882-4A BR0316882A (pt) 2002-12-23 2003-12-18 Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas

Country Status (22)

Country Link
US (2) US7332303B2 (pt)
EP (1) EP1576182B2 (pt)
JP (1) JP4496086B2 (pt)
KR (1) KR101088223B1 (pt)
CN (1) CN100402660C (pt)
AT (1) ATE488600T1 (pt)
AU (1) AU2003303394B2 (pt)
BR (1) BR0316882A (pt)
CA (1) CA2508925C (pt)
CO (1) CO5590971A2 (pt)
CY (1) CY1111358T1 (pt)
DE (1) DE60335024D1 (pt)
DK (1) DK1576182T4 (pt)
ES (1) ES2354610T5 (pt)
HK (1) HK1075474A1 (pt)
IL (1) IL168873A (pt)
MX (1) MXPA05006522A (pt)
PL (1) PL377603A1 (pt)
PT (1) PT1576182E (pt)
SI (1) SI1576182T2 (pt)
TW (1) TWI328614B (pt)
WO (1) WO2004058944A2 (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2447921C (en) 2001-05-23 2011-08-09 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
DK1623023T3 (da) * 2003-05-09 2009-03-02 Crucell Holland Bv Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
SG144925A1 (en) 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
CN101198347A (zh) 2005-04-06 2008-06-11 布里斯托尔-迈尔斯斯奎布公司 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
UA97469C2 (uk) * 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
HRP20131196T4 (hr) * 2005-12-20 2022-06-10 Bristol-Myers Squibb Company Stabilne formulacije proteina
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
BRPI0620178B1 (pt) * 2005-12-20 2022-08-23 Bristol-Myers Squibb Company Composições compreendendo moléculas de ctla4-ig
US10167332B2 (en) * 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8093045B2 (en) 2006-09-13 2012-01-10 Abbott Laboratories Fed-batch cell culture methods using non-animal-based hydrolysates
EP2091969A4 (en) * 2006-10-27 2010-05-12 Univ Rockefeller POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2385065A1 (en) * 2007-11-01 2011-11-09 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
EP2279410B1 (en) 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
WO2012149197A2 (en) * 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
EP2809772A4 (en) * 2012-01-30 2015-06-03 Reddys Lab Ltd Dr PROCESS FOR PREPARING GLYCOPROTEIN COMPOSITION
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
EP2844737B1 (en) 2012-05-02 2018-03-21 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SI2867251T1 (sl) 2012-06-29 2019-12-31 Bristol-Myers Squibb Company Postopki za zmanjšanje agregacije glikoproteina
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
KR20150054850A (ko) * 2012-08-23 2015-05-20 닛산 가가쿠 고교 가부시키 가이샤 단백질 산생 촉진제
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015116820A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
CN106456712A (zh) 2014-04-25 2017-02-22 百时美施贵宝公司 Ctla4化合物用于在具有早期ra的受试者中实现无药物缓解的用途
KR102434588B1 (ko) * 2014-06-18 2022-08-22 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
TR201903267T4 (tr) 2014-10-15 2019-03-21 Alexion Pharma Inc Büyük ölçekli eculizumab üretim hücre kültürünün replikasyon metotları.
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
US20170016043A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US11401509B2 (en) 2015-11-09 2022-08-02 Bristol-Myers Squibb Company Methods of minimizing glycoprotein agregation in CHO cell production
KR20230125857A (ko) * 2016-06-02 2023-08-29 클로토 테라퓨틱스, 아이엔씨. 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물및 방법
AU2017363321B2 (en) 2016-11-22 2023-09-28 Klotho Therapeutics, Inc. Novel recombinant Klotho proteins and compositions and methods involving the same
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
EA202092576A1 (ru) 2018-05-01 2021-02-05 Эмджен Инк. Антитела с модулированными гликановыми профилями
CN111321188A (zh) * 2018-12-17 2020-06-23 嘉和生物药业有限公司 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用
IL288367B2 (en) 2019-12-06 2023-02-01 Regeneron Pharma Anti-vegf protein preparations and methods for their production
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
CN111676184B (zh) * 2020-05-15 2021-01-29 上海多宁生物科技有限公司 一种由补料培养基共混的基础培养基及其制备方法和应用
KR20230042125A (ko) * 2020-08-14 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 단백질에 대한 제조 공정
EP4284914A1 (en) * 2021-02-01 2023-12-06 Dr. Reddy's Laboratories Limited Cell culture methods
CN116830204A (zh) 2021-02-08 2023-09-29 株式会社岛津制作所 估计装置、学习装置、优化装置、估计方法、学习方法以及优化方法
WO2024129594A1 (en) * 2022-12-12 2024-06-20 Genentech, Inc. Optimizing polypeptide sialic acid content

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
FR2543158B1 (fr) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4994387A (en) * 1983-11-10 1991-02-19 The Wistar Institute Process and medium for cloning and long-term serial cultivation of human endothelial cells
US5132223A (en) * 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
GB9022545D0 (en) † 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5318898A (en) * 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
TW318142B (pt) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
ATE170562T1 (de) * 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP1488805A2 (en) 1992-04-07 2004-12-22 The Regents of the University of Michigan CD28 pathway immunoregulation
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US5348877A (en) * 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
EP0763057B1 (en) * 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for proliferating and differentiating b cells, and uses thereof
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0817842A1 (en) * 1995-03-24 1998-01-14 Takeda Chemical Industries, Ltd. Antibody to human betacellulin and use thereof
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5817290A (en) * 1995-07-28 1998-10-06 Beth Israel Deaconess Medical Center Method of and test kit for mutagenesis testing
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5728580A (en) * 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
CA2246352C (en) * 1996-03-20 2011-11-08 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
EP1036179B2 (de) † 1997-12-03 2014-01-01 Roche Diagnostics GmbH Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
ATE314485T1 (de) 1998-05-29 2006-01-15 Genentech Inc Zellkulturverfahren für die produktion von glycoproteinen
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AU773845B2 (en) * 1998-11-18 2004-06-10 Neose Technologies, Inc. Low cost manufacture of oligosaccharides
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
AU2001236739A1 (en) 2000-02-08 2001-08-20 Genentech Inc. Improved sialylation of glycoproteins
ES2266159T3 (es) 2000-02-08 2007-03-01 Genentech, Inc. Mejora de la galactosilacion de glicoproteinas recombinantes.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EG24459A (en) * 2000-05-26 2009-07-16 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof
AU7541101A (en) * 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2310557T3 (es) * 2000-07-03 2009-01-16 Bristol-Myers Squibb Company Procedimiento para tratar enfermedades reumaticas usando una molecula de ctla4 soluble.
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CA2447921C (en) * 2001-05-23 2011-08-09 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
DK1543106T3 (da) † 2002-07-15 2007-08-13 Immunex Corp Fremgangsmåder og medier til kontrol af sialylering af proteiner, der dannes af mammaliaceller
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
SG144925A1 (en) 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2008060307A2 (en) * 2006-01-09 2008-05-22 Wyeth Methods of labeling transiently expressed proteins in large-scale eukaryotic cell cultures

Also Published As

Publication number Publication date
CO5590971A2 (es) 2005-12-30
CN1820080A (zh) 2006-08-16
KR101088223B1 (ko) 2011-11-30
KR20050103466A (ko) 2005-10-31
WO2004058944A2 (en) 2004-07-15
AU2003303394B2 (en) 2009-02-19
DK1576182T3 (da) 2011-02-21
PT1576182E (pt) 2011-01-21
ES2354610T5 (es) 2020-09-14
PL377603A1 (pl) 2006-02-06
EP1576182B1 (en) 2010-11-17
SI1576182T1 (sl) 2011-01-31
JP2006511224A (ja) 2006-04-06
AU2003303394A1 (en) 2004-07-22
DK1576182T4 (da) 2020-04-20
CN100402660C (zh) 2008-07-16
CY1111358T1 (el) 2015-08-05
CA2508925A1 (en) 2004-07-15
JP4496086B2 (ja) 2010-07-07
WO2004058944A8 (en) 2005-07-21
US20080070280A1 (en) 2008-03-20
CA2508925C (en) 2012-08-28
TWI328614B (en) 2010-08-11
EP1576182B2 (en) 2020-01-15
ES2354610T3 (es) 2011-03-16
US20050084933A1 (en) 2005-04-21
HK1075474A1 (en) 2005-12-16
EP1576182A4 (en) 2007-05-02
DE60335024D1 (de) 2010-12-30
EP1576182A2 (en) 2005-09-21
MXPA05006522A (es) 2006-02-17
ATE488600T1 (de) 2010-12-15
WO2004058944A3 (en) 2004-09-10
TW200504221A (en) 2005-02-01
US7332303B2 (en) 2008-02-19
IL168873A (en) 2013-04-30
SI1576182T2 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
BR0316882A (pt) Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
TW200512297A (en) Mammalian cell culture processes for protein production
Ljunggren et al. Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures
BRPI0409895B8 (pt) método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células
JP6347949B2 (ja) 改良型細胞培養培地
EA201490631A1 (ru) Способы культивирования клеток млекопитающих для получения белка
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
SI1543106T1 (sl) Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
UA92157C2 (ru) Способ продуцирования гормона роста
WO2005028626A3 (en) Cell culture media
EP4349959A1 (en) Composition for culturing algae and algae culturing method
BRPI0517942A (pt) meio de cultura de células isento de soro para células de mamìferos
NZ515762A (en) Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions
ATE292688T1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
Zagris Deoxycytidine reverses inhibition of morphogenesis by thymidine in young chick blastoderm
Franěk et al. Increasing monoclonal antibody productivity by semicontinuous substitution of production medium for growth medium
GB9828624D0 (en) Production of proteins
ŠRÁMKOVÁ INCREASING MONOCLONAL ANTIBODY PRODUCTIVITY BY SEMICONTINUOUS SUBSTITUTION OF PRODUCTION MEDIUM FOR GROWTH MEDIUM
UA81564C2 (ru) Способ дифференциации стромальных столбовых клеток человека в культуральной среде in vitro
CN104830750A (zh) 一种驴皮成纤维细胞体外快速培养的方法
UY26907A1 (es) Proceso para preparar un factor inhibidor de neutrófilos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]